QRG Capital Management Inc. Has $8.78 Million Holdings in Sanofi (NASDAQ:SNY)

QRG Capital Management Inc. raised its holdings in Sanofi (NASDAQ:SNY) by 8.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 152,406 shares of the company’s stock after acquiring an additional 12,245 shares during the period. QRG Capital Management Inc.’s holdings in Sanofi were worth $8,783,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Manning & Napier Advisors LLC bought a new stake in Sanofi during the 2nd quarter worth $13,725,000. Mount Yale Investment Advisors LLC increased its stake in shares of Sanofi by 44.3% in the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after buying an additional 12,806 shares during the period. Jennison Associates LLC grew its holdings in Sanofi by 18.9% during the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock worth $9,216,000 after acquiring an additional 30,115 shares during the last quarter. Sei Investments Co. increased its position in Sanofi by 9.3% in the 1st quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock valued at $26,926,000 after acquiring an additional 47,297 shares during the period. Finally, Atria Investments Inc raised its stake in shares of Sanofi by 31.1% during the first quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock valued at $4,805,000 after acquiring an additional 23,463 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Ratings Changes

SNY has been the subject of a number of recent research reports. StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 30th. Argus increased their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $57.50.

Sanofi Stock Performance

Shares of Sanofi stock opened at $52.95 on Tuesday. The company has a market cap of $134.38 billion, a P/E ratio of 27.02, a PEG ratio of 1.36 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The business has a 50-day moving average price of $55.85 and a two-hundred day moving average price of $52.10. Sanofi has a 1-year low of $45.00 and a 1-year high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business’s revenue was up 12.3% on a year-over-year basis. During the same period last year, the company earned $2.55 earnings per share. As a group, analysts anticipate that Sanofi will post 4.27 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.